Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Sally Greenberg Comments.

Greenberg SJ.

Am J Public Health. 2020 Apr;110(4):445-446. doi: 10.2105/AJPH.2020.305589. No abstract available.

PMID:
32159986
2.

Medical history: as it was; as it will be.

Greenberg SJ.

J Med Libr Assoc. 2020 Jan;108(1):143-146. doi: 10.5195/jmla.2020.850. Epub 2020 Jan 1.

3.

Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis.

Rose JW, Giovannoni G, Wiendl H, Gold R, Havrdová E, Kappos L, Selmaj KW, Zhao J, Riester K, Tsao LC, Greenberg SJ.

Mult Scler Relat Disord. 2017 Oct;17:32-40. doi: 10.1016/j.msard.2017.06.006. Epub 2017 Jun 19.

PMID:
29055471
4.

Between the sheets.

Greenberg SJ.

J Med Libr Assoc. 2017 Oct;105(4):400-403. doi: 10.5195/jmla.2017.195. Epub 2017 Oct 1. No abstract available.

5.

Circulating lymphocyte levels and relationship with infection status in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta.

Giovannoni G, Wiendl H, Turner B, Umans K, Mokliatchouk O, Castro-Borrero W, Greenberg SJ, McCroskery P, Giannattasio G.

Mult Scler. 2018 Nov;24(13):1725-1736. doi: 10.1177/1352458517729464. Epub 2017 Sep 15.

PMID:
28914581
6.

Whither Sir William?

Greenberg SJ.

J Med Libr Assoc. 2017 Apr;105(2):194-195. doi: 10.5195/jmla.2017.225. No abstract available.

7.

History matters.

Greenberg SJ.

J Med Libr Assoc. 2017 Jan;105(1):89. doi: 10.5195/jmla.2017.112. No abstract available.

8.

No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study.

Kappos L, Havrdova E, Giovannoni G, Khatri BO, Gauthier SA, Greenberg SJ, You X, Wang P, Giannattasio G.

Mult Scler. 2017 Nov;23(13):1736-1747. doi: 10.1177/1352458516683266. Epub 2016 Dec 22.

PMID:
28080250
9.

Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies.

Giovannoni G, Kappos L, Gold R, Khatri BO, Selmaj K, Umans K, Greenberg SJ, Sweetser M, Elkins J, McCroskery P.

Mult Scler Relat Disord. 2016 Sep;9:36-46. doi: 10.1016/j.msard.2016.05.010. Epub 2016 May 11.

10.

Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study.

Gold R, Radue EW, Giovannoni G, Selmaj K, Havrdova E, Stefoski D, Sprenger T, Montalban X, Cohan S, Umans K, Greenberg SJ, Ozen G, Elkins J.

BMC Neurol. 2016 Jul 26;16:117. doi: 10.1186/s12883-016-0635-y.

11.

Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis.

Krueger JG, Kircik L, Hougeir F, Friedman A, You X, Lucas N, Greenberg SJ, Sweetser M, Castro-Borrero W, McCroskery P, Elkins J.

Adv Ther. 2016 Jul;33(7):1231-45. doi: 10.1007/s12325-016-0353-2. Epub 2016 Jun 1.

12.

Fludarabine add-on therapy in interferon-beta-treated patients with multiple sclerosis experiencing breakthrough disease.

Greenberg SJ, Zivadinov R, Lee-Kwen P, Sharma J, Planter M, Umhauer M, Glenister N, Bakshi R.

Ther Adv Neurol Disord. 2016 Mar;9(2):105-17. doi: 10.1177/1756285615626049. Epub 2016 Jan 21.

13.

Fluoroscopy-free Atrial Transseptal Puncture.

McCauley MD, Patel N, Greenberg SJ, Molina-Razavi JE, Safavi-Naeini P, Razavi M.

Eur J Arrhythm Electrophysiol. 2016 Winter;2(2):57-61. doi: 10.17925/EJAE.2016.02.02.57.

14.

MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study.

Comi G, Cook SD, Giovannoni G, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, Hamlett AC, Viglietta V, Greenberg SJ.

J Neurol. 2013 Apr;260(4):1136-46. doi: 10.1007/s00415-012-6775-0. Epub 2012 Dec 21.

PMID:
23263473
15.

Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis.

Comi G, Hartung HP, Kurukulasuriya NC, Greenberg SJ, Scaramozza M.

Expert Opin Pharmacother. 2013 Jan;14(1):123-36. doi: 10.1517/14656566.2013.754012. Epub 2012 Dec 21. Review.

PMID:
23256518
16.

Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.

Cook S, Vermersch P, Comi G, Giovannoni G, Rammohan K, Rieckmann P, Sørensen PS, Hamlett A, Miret M, Weiner J, Viglietta V, Musch B, Greenberg SJ; CLARITY Study Group.

Mult Scler. 2011 May;17(5):578-93. doi: 10.1177/1352458510391344. Epub 2011 Jan 12.

PMID:
21228029
17.

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.

Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ; CLARITY Study Group.

N Engl J Med. 2010 Feb 4;362(5):416-26. doi: 10.1056/NEJMoa0902533. Epub 2010 Jan 20.

18.

Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse.

Diener HC, Dodick DW, Goadsby PJ, Bigal ME, Bussone G, Silberstein SD, Mathew N, Ascher S, Morein J, Hulihan JF, Biondi DM, Greenberg SJ.

Cephalalgia. 2009 Oct;29(10):1021-7. doi: 10.1111/j.1468-2982.2009.01859.x. Epub 2009 Apr 23. Review.

PMID:
19735529
19.

Estrogen increases survival in an orthotopic model of glioblastoma.

Barone TA, Gorski JW, Greenberg SJ, Plunkett RJ.

J Neurooncol. 2009 Oct;95(1):37-48. doi: 10.1007/s11060-009-9904-6. Epub 2009 May 5.

PMID:
19415456
20.

The great contribution: Index Medicus, Index-Catalogue, and IndexCat.

Greenberg SJ, Gallagher PE.

J Med Libr Assoc. 2009 Apr;97(2):108-13. doi: 10.3163/1536-5050.97.2.007.

21.

Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs.

Dodick DW, Freitag F, Banks J, Saper J, Xiang J, Rupnow M, Biondi D, Greenberg SJ, Hulihan J; CAPSS-277 Investigator Group.

Clin Ther. 2009 Mar;31(3):542-59. doi: 10.1016/j.clinthera.2009.03.020.

PMID:
19393844
22.

Allodynia-associated symptoms, pain intensity and time to treatment: predicting treatment response in acute migraine intervention.

Cady RK, Freitag FG, Mathew NT, Elkind AH, Mao L, Fisher AC, Biondi DM, Finlayson G, Greenberg SJ, Hulihan JF.

Headache. 2009 Mar;49(3):350-63. doi: 10.1111/j.1526-4610.2009.01340.x. Epub 2009 Feb 11.

PMID:
19220503
23.

Characteristics of migraine attacks and responses to almotriptan treatment: a comparison of menstrually related and nonmenstrually related migraines.

Diamond ML, Cady RK, Mao L, Biondi DM, Finlayson G, Greenberg SJ, Wright P.

Headache. 2008 Feb;48(2):248-58. doi: 10.1111/j.1526-4610.2007.01019.x.

PMID:
18234046
24.

The impact of topiramate on health-related quality of life indicators in chronic migraine.

Dodick DW, Silberstein S, Saper J, Freitag FG, Cady RK, Rapoport AM, Mathew NT, Hulihan J, Crivera C, Rupnow MF, Mao L, Finlayson G, Greenberg SJ.

Headache. 2007 Nov-Dec;47(10):1398-408.

PMID:
18052949
25.

Effect of pain intensity and time to administration on responsiveness to almotriptan: results from AXERT 12.5 mg Time Versus Intensity Migraine Study (AIMS).

Freitag FG, Finlayson G, Rapoport AM, Elkind AH, Diamond ML, Unger JR, Fisher AC, Armstrong RB, Hulihan JF, Greenberg SJ; AIMS Investigators.

Headache. 2007 Apr;47(4):519-30.

PMID:
17445101
26.

Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study).

Mathew NT, Finlayson G, Smith TR, Cady RK, Adelman J, Mao L, Wright P, Greenberg SJ; AEGIS Investigator Study Group.

Headache. 2007 Feb;47(2):189-98.

PMID:
17300358
27.

Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.

Silberstein SD, Lipton RB, Dodick DW, Freitag FG, Ramadan N, Mathew N, Brandes JL, Bigal M, Saper J, Ascher S, Jordan DM, Greenberg SJ, Hulihan J; Topiramate Chronic Migraine Study Group.

Headache. 2007 Feb;47(2):170-80.

PMID:
17300356
28.

Assessing the ability of topiramate to improve the daily activities of patients with migraine.

Brandes JL, Kudrow DB, Rothrock JF, Rupnow MF, Fairclough DL, Greenberg SJ.

Mayo Clin Proc. 2006 Oct;81(10):1311-9.

PMID:
17036556
29.

Reduction in asthma morbidity in children as a result of home remediation aimed at moisture sources.

Kercsmar CM, Dearborn DG, Schluchter M, Xue L, Kirchner HL, Sobolewski J, Greenberg SJ, Vesper SJ, Allan T.

Environ Health Perspect. 2006 Oct;114(10):1574-80.

30.

Increased expression of TGF-beta1 reduces tumor growth of human U-87 Glioblastoma Cells in vivo.

Pan JJ, Chang WJ, Barone TA, Plunkett RJ, Ostrow PT, Greenberg SJ.

Cancer Immunol Immunother. 2006 Aug;55(8):918-27. Epub 2005 Sep 27.

PMID:
16187082
31.

Multiple sclerosis characteristics in African American patients in the New York State Multiple Sclerosis Consortium.

Weinstock-Guttman B, Jacobs LD, Brownscheidle CM, Baier M, Rea DF, Apatoff BR, Blitz KM, Coyle PK, Frontera AT, Goodman AD, Gottesman MH, Herbert J, Holub R, Lava NS, Lenihan M, Lusins J, Mihai C, Miller AE, Perel AB, Snyder DH, Bakshi R, Granger CV, Greenberg SJ, Jubelt B, Krupp L, Munschauer FE, Rubin D, Schwid S, Smiroldo J; New York State Multiple Sclerosis Consortium.

Mult Scler. 2003 Jun;9(3):293-8.

PMID:
12814178
32.

Syngeneic central nervous system transplantation of genetically transduced mature, adult astrocytes.

Selkirk SM, Greenberg SJ, Plunkett RJ, Barone TA, Lis A, Spence PO.

Gene Ther. 2002 Apr;9(7):432-43.

33.

Orbital involvement as the initial manifestation of sarcoidosis: magnetic resonance imaging findings.

Shaikh ZA, Bakshi R, Greenberg SJ, Fine EJ, Shatla A, Lincoff NS.

J Neuroimaging. 2000 Jul;10(3):180-3.

PMID:
10918747
34.

A profile of multiple sclerosis: the New York State Multiple Sclerosis Consortium.

Jacobs LD, Wende KE, Brownscheidle CM, Apatoff B, Coyle PK, Goodman A, Gottesman MH, Granger CV, Greenberg SJ, Herbert J, Krupp L, Lava NS, Mihai C, Miller AE, Perel A, Smith CR, Snyder DH.

Mult Scler. 1999 Oct;5(5):369-76.

PMID:
10516782
35.

Hormonal effects on glioblastoma multiforme in the nude rat model.

Plunkett RJ, Lis A, Barone TA, Fronckowiak MD, Greenberg SJ.

J Neurosurg. 1999 Jun;90(6):1072-7.

PMID:
10350254
36.

Leber's hereditary optic neuropathy mitochondrial DNA mutations in familial multiple sclerosis.

Mojon DS, Fujihara K, Hirano M, Miller C, Lincoff NS, Jacobs LD, Greenberg SJ.

Graefes Arch Clin Exp Ophthalmol. 1999 Apr;237(4):348-50.

PMID:
10208269
37.

Intratumoral infusion of topotecan prolongs survival in the nude rat intracranial U87 human glioma model.

Pollina J, Plunkett RJ, Ciesielski MJ, Lis A, Barone TA, Greenberg SJ, Fenstermaker RA.

J Neurooncol. 1998 Sep;39(3):217-25.

PMID:
9821107
38.
39.

An experimental model of human leukemic meningitis in the nude rat.

Barone TA, Plunkett RJ, Hohmann P, Lis A, Glenister N, Barcos M, Ostrow PT, Spence PM, Greenberg SJ.

Blood. 1997 Jul 1;90(1):298-305.

PMID:
9207465
40.

Retinoic acid-induced modulation of IL-2 mRNA production and IL-2 receptor expression on T cells.

Ballow M, Xiang S, Greenberg SJ, Brodsky L, Allen C, Rich G.

Int Arch Allergy Immunol. 1997 May-Jul;113(1-3):167-9.

PMID:
9130512
41.

Pleiotropic expression of heterologous cytokine/receptor genes in HTLV-1 associated diseases: candidate TRS for chimeric gene therapy.

Greenberg SJ, Choi U, Overturf PM, Glenister N, Robinson TA, Lis A, Hohmann P, Goldman BD, Oseroff AR, Plunkett RJ.

Leukemia. 1997 Apr;11 Suppl 3:79-81.

PMID:
9209305
42.

Correlation of endothelin-1 and transforming growth factor beta 1 with malignancy and vascularity in human gliomas.

Stiles JD, Ostrow PT, Balos LL, Greenberg SJ, Plunkett R, Grand W, Heffner RR Jr.

J Neuropathol Exp Neurol. 1997 Apr;56(4):435-9.

PMID:
9100674
44.

HTLV-associated diseases: human retroviral infection and cutaneous T-cell lymphomas.

Fujihara K, Goldman B, Oseroff AR, Glenister N, Jaffe ES, Bisaccia E, Pincus S, Greenberg SJ.

Immunol Invest. 1997 Jan-Feb;26(1-2):231-42.

PMID:
9037626
45.

Polymerase chain reaction assays for the detection of cytomegalovirus in organ and bone marrow transplant recipients.

Evans MJ, Edwards-Spring Y, Myers J, Wendt A, Povinelli D, Amsterdam D, Rittenhouse-Diakun K, Armstrong D, Murray BM, Greenberg SJ, Riepenhoff-Talty M.

Immunol Invest. 1997 Jan-Feb;26(1-2):209-29.

PMID:
9037625
46.

Novel compound tetra-, dinucleotide microsatellite polymorphism in the tumor necrosis factor/lymphotoxin locus.

Greenberg SJ, Fujihara K, Selkirk SM, Yu F, Du TL, Glenister N, Hohmann P, Rickert MH, Spence PO, Miller CE, Jacobs LD.

Clin Diagn Lab Immunol. 1997 Jan;4(1):79-84.

47.

Detection of group C rotavirus in infants with extrahepatic biliary atresia.

Riepenhoff-Talty M, Gouvea V, Evans MJ, Svensson L, Hoffenberg E, Sokol RJ, Uhnoo I, Greenberg SJ, Schäkel K, Zhaori G, Fitzgerald J, Chong S, el-Yousef M, Nemeth A, Brown M, Piccoli D, Hyams J, Ruffin D, Rossi T.

J Infect Dis. 1996 Jul;174(1):8-15.

PMID:
8656017
48.

Clonal evolution in B-lineage acute lymphoblastic leukemia by contemporaneous VH-VH gene replacements and VH-DJH gene rearrangements.

Choi Y, Greenberg SJ, Du TL, Ward PM, Overturf PM, Brecher ML, Ballow M.

Blood. 1996 Mar 15;87(6):2506-12.

PMID:
8630417
49.

Immune responses in patients with T-cell lymphoma treated with an anti-idiotype antibody mimicking a highly restricted T-cell antigen.

Foon KA, Oseroff AR, Vaickus L, Greenberg SJ, Russell D, Bernstein Z, Pincus S, Köhler H, Seon BK, Tahaoglu E, et al.

Clin Cancer Res. 1995 Nov;1(11):1285-94.

50.

Human IgH-V gene repertoire in neonatal cord blood, adult peripheral blood, and EBV-transformed cells.

Choi Y, Rickert MH, Ballow M, Greenberg SJ.

Ann N Y Acad Sci. 1995 Sep 29;764:261-4. No abstract available.

PMID:
7486533

Supplemental Content

Loading ...
Support Center